866-997-4948(US-Canada Toll Free)

Keloids - Pipeline Review, H2 2016

Published By :

Global Markets Direct

Published Date : Dec 2016

Category :

Pharmaceutical

No. of Pages : 53 Pages

Keloids - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Keloids Pipeline Review, H2 2016, provides an overview of the Keloids (Keloids) pipeline landscape.

Keloids are a growth of extra scar tissue where the skin has healed after an injury. Symptoms include flesh-colored, red, or pink, lumpy (nodular) or ridged, irritated from friction such as rubbing on clothing and tender and itchy. Risk factors include age and family history. Treatment includes corticosteroid, radiation, surgical removal and silicone gel or patches.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Keloids Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Keloids (Keloids), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Keloids (Keloids) pipeline guide also reviews of key players involved in therapeutic development for Keloids and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 2, 4 and 1 respectively. Similarly, the Universities portfolio in Discovery stages comprises 2 molecules, respectively.

Keloids (Keloids) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Keloids (Keloids).
- The pipeline guide reviews pipeline therapeutics for Keloids (Keloids) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Keloids (Keloids) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Keloids (Keloids) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Keloids (Keloids)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Keloids (Keloids).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Keloids (Keloids) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Keloids Overview 6
Therapeutics Development 7
Pipeline Products for Keloids - Overview 7
Pipeline Products for Keloids - Comparative Analysis 8
Keloids - Therapeutics under Development by Companies 9
Keloids - Therapeutics under Investigation by Universities/Institutes 10
Keloids - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Keloids - Products under Development by Companies 13
Keloids - Products under Investigation by Universities/Institutes 14
Keloids - Companies Involved in Therapeutics Development 15
FirstString Research Inc 15
RXi Pharmaceuticals Corp 16
Topadur Pharma AG 17
Tumorend LLC 18
viDA Therapeutics Inc 19
Yuhan Corp 20
Keloids - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
CM-101 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
Granexin - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
koebnerisin - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
psoriasin - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
RXI-109 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
TOPN-44 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
V-2248 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
VTI-3000 Series - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
YH-siRNA1 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
Keloids - Dormant Projects 45
Keloids - Discontinued Products 46
Keloids - Product Development Milestones 47
Featured News & Press Releases 47
Jun 02, 2015: RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology 47
Apr 29, 2014: RXi Pharmaceuticals Announces Initiation of Phase 2a Keloid Study 47
Mar 05, 2014: RXi Pharmaceuticals Granted Key Patent Related to Self-Delivering Technology for the Treatment of Fibrotic Disorders 48
Dec 04, 2013: RXi Pharmaceuticals Announces mRNA Data of an Additional Cohort in the Second Phase 1 Multi-Dose Study with RXI-109, Extending the Dose Response Following Treatment in the Initial 2-week Period 48
Nov 18, 2013: RXi Pharmaceuticals and Ethicor Announce the Signing of a Distribution Agreement for RXI-109 in the European Union under the "Specials" Provision 49
Jun 06, 2013: RXi Pharmaceuticals Announces Positive Results In First Double Blind Study In Healthy Volunteers With RXI-109 49
Jan 30, 2013: RXi Pharma Completes Enrollment In Second Phase I Trial For RXI-109 Program 50
Appendix 52
Methodology 52
Coverage 52
Secondary Research 52
Primary Research 52
Expert Panel Validation 52
Contact Us 52
Disclaimer 53

List of Tables
Number of Products under Development for Keloids, H2 2016 7
Number of Products under Development for Keloids - Comparative Analysis, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Number of Products under Investigation by Universities/Institutes, H2 2016 10
Comparative Analysis by Clinical Stage Development, H2 2016 11
Comparative Analysis by Early Stage Development, H2 2016 12
Products under Development by Companies, H2 2016 13
Products under Investigation by Universities/Institutes, H2 2016 14
Keloids - Pipeline by FirstString Research Inc, H2 2016 15
Keloids - Pipeline by RXi Pharmaceuticals Corp, H2 2016 16
Keloids - Pipeline by Topadur Pharma AG, H2 2016 17
Keloids - Pipeline by Tumorend LLC, H2 2016 18
Keloids - Pipeline by viDA Therapeutics Inc, H2 2016 19
Keloids - Pipeline by Yuhan Corp, H2 2016 20
Assessment by Monotherapy Products, H2 2016 21
Number of Products by Stage and Target, H2 2016 23
Number of Products by Stage and Mechanism of Action, H2 2016 25
Number of Products by Stage and Route of Administration, H2 2016 27
Number of Products by Stage and Molecule Type, H2 2016 29
Keloids - Dormant Projects, H2 2016 45
Keloids - Discontinued Products, H2 2016 46

List of Figures
Number of Products under Development for Keloids, H2 2016 7
Number of Products under Development for Keloids - Comparative Analysis, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Comparative Analysis by Early Stage Products, H2 2016 12
Assessment by Monotherapy Products, H2 2016 21
Number of Products by Targets, H2 2016 22
Number of Products by Stage and Targets, H2 2016 22
Number of Products by Mechanism of Actions, H2 2016 24
Number of Products by Stage and Mechanism of Actions, H2 2016 24
Number of Products by Routes of Administration, H2 2016 26
Number of Products by Stage and Routes of Administration, H2 2016 26
Number of Products by Molecule Types, H2 2016 28
Number of Products by Stage and Molecule Types, H2 2016 28

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *